CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

NCT02259556 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma

Interventions

BIOLOGICAL: CART30

Sponsor

Chinese PLA General Hospital